Advocacy intelligence hub — real-time data for patient organizations
Virginia Commonwealth University — NA
Queen Mary University of London — NA
Portuguese Association of Interventional Cardiology
Claudia R. Morris — PHASE2
Autus Valve Technologies, Inc. — NA
Catharina Ziekenhuis Eindhoven — NA
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
I.M. Sechenov First Moscow State Medical University
HeartFlow, Inc.
Universitat Internacional de Catalunya — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Enjaymo
(SUTIMLIMAB-JOME)Orphan drugstandardRecordati Rare Diseases, Inc.
Classical Complement Pathway Inhibitor [EPC]
12.1 Mechanism of Action Sutimlimab-jome is an immunoglobulin G (IgG), subclass 4 (IgG4) monoclonal antibody (mAb) that inhibits the classical complem...
Jacqueline Saw, MD
University of British Columbia
Ronald G Crystal, MD, MD
Weill Medical College of Cornell University
📍 NEW YORK, NY
Henrik Birgens, MD, PhD
Herlev University Hospital, Copenhagen, Denmark
Giuseppe Rossi, Dr.
S.C. Ematologia e Dipartimento di Oncologia Medica Spedali Civili - Brescia
Markku Oksman, MD
Turku University Hospital, Turku, Finland
Alexander Roeth, MD
Department of Hematology, University Hospital Essen